NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Kala Bio, Inc. KALA
11 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-27.0M
Growth
—
Revenue, FY2025 · full 11-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -27.0
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2022 · Operating -2099.3% · Net -1151.6%
ROE
FY2025 · ROE -279.2%
Each USD of equity lost 279 cents this year.
The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | · | · | · | · | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −3.31 | −10.15 | −17.35 | −29.48 | −108.32 | −1.99 | −2.76 | −2.49 | −3.71 | −28.07 | −14.89 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −279.2 | −388.3 | −318.7 | −250.6 | −244.2 | −160.9 | −140.1 | −68.6 | −4403.9 | · | · |
| Shares out B | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.06 | 0.04 | 0.03 | 0.02 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 42 reconciliationsAUDITED
Reconciled in 11 of 19 fiscal years. 34 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2015